Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Hodgkin’s lymphoma drug to launch soon

By News team

Brentuximab vedotin is due to be launched next week (19 November 2012) for the treatment of relapsed or refractory Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma.

The new medicine will be available from Takeda and will be marketed as Adcetris.

Brentuximab vedotin is a monoclonal antibody attached to an antimicrotubule agent that kills the target cancer cells. The antibody is specific for the CD30+ protein expressed on the surface of Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma cells.

Brentuximab vedotin is administered every three weeks by intravenous infusion over 30 minutes at a dose of 1.8mg/kg body weight. Treatment is recommended to continue until disease progression or unacceptable toxicity occurs. In patients with stable (or better) disease a minimum of eight cycles and a maximum of 16 cycles should be completed.

In two open-label, single-arm, multicentre studies, brentuximab vedotin resulted in a 75 per cent response rate in Hodgkin’s lymphoma patients and an 86 per cent response rate in systemic anaplastic large cell lymphoma patients.

The most common side effects of brentuximab vedotin are infections, according to the summary of product characteristics. However a rarer, often fatal condition, progressive multifocal leukoencephalopathy has been reported outside of clinical trials in patients who had also received multiple prior chemotherapy regimens.

Adcetris is indicated for treatment of adult patients with relapsed or refractory CD30+ Hodgkin’s lymphoma following autologous stem cell transplant, or following at least two prior therapies, when autologous stem cell transplant or multi-agent chemotherapy are not a treatment option. It is also indicated for adult patients with relapsed or refractory systemic large cell lymphoma.

Product details

Class: Antibody-drug conjugate
Dose: 1.8mg/kg as intravenous infusion over 30 minutes every three weeks
NHS list price: £2,500 per vial of 50mg powder for concentrate for solution for infusion
Legal category: POM

Citation: The Pharmaceutical Journal URI: 11111588

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Adcetris: an antibody-drug conjugate

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.